Identification

Name
Desonide
Accession Number
DB01260
Type
Small Molecule
Groups
Approved, Investigational
Description

A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem]

Structure
Thumb
Synonyms
  • 11beta,21-Dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
  • 11beta,21-Dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
  • 11beta,21-Dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
  • 16alpha-Hydroxyprednisole-16,17-acetonide
  • 16alpha-Hydroxyprednisolone-16alpha,17-acetonide
  • 16alpha,17alpha-Isopropylidenedioxyprednisolone
  • Desfluorotriamcinolone acetonide
  • Desonida
  • Desonidum
External IDs
D-2083 / D2083
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desocort Cream 0.05%Cream.05 %TopicalGalderma1994-12-312007-08-02Canada
Desocort Lotion - 0.05%Lotion.05 %TopicalGalderma1994-12-312016-08-04Canada
Desocort Ointment - 0.05%Ointment.05 %TopicalGalderma1994-12-312016-08-04Canada
DesonateGel.5 mg/gTopicalBayer2006-10-20Not applicableUs
DesonateGel.5 mg/gTopicalIntendis Inc.2010-01-28Not applicableUs
DesonideOintment.5 mg/gTopicalPerrigo New York Inc.2006-08-22Not applicableUs
DesonideCream.5 mg/gTopicalPhysicians Total Care, Inc.2006-04-11Not applicableUs
DesonideCream.5 mg/gTopicalPerrigo New York Inc.2006-04-11Not applicableUs
DesonideCream.5 mg/gTopicalRebel Distributors2006-04-11Not applicableUs
DesonideOintment.5 mg/gTopicalPhysicians Total Care, Inc.2006-06-21Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesonideLotion.5 mg/gTopicalPhysicians Total Care, Inc.2004-05-17Not applicableUs
DesonideOintment.5 mg/gTopicalGlenmark Pharmaceuticals Inc.,Usa2017-09-15Not applicableUs
DesonideCream.5 mg/gTopicalGw Pharmaceuticals Ltd.2015-06-29Not applicableUs
DesonideCream.5 mg/gTopicalGlenmark Pharmaceuticals Inc.,Usa2017-07-24Not applicableUs
DesonideCream.5 mg/gTopicalOwen Laboratories1984-12-14Not applicableUs
DesonideOintment.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2001-03-12Not applicableUs
DesonideCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1992-06-30Not applicableUs
DesonideLotion.5 mg/mLTopicalGlenmark Pharmaceuticals Inc.,Usa2017-09-26Not applicableUs
DesonideCream.5 mg/gTopicalActavis Pharma Company2013-08-01Not applicableUs
DesonideLotion.5 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2014-10-31Not applicableUs
International/Other Brands
Desocort (Galderma) / Tridesilon (Bayer)
Categories
UNII
J280872D1O
CAS number
638-94-8
Weight
Average: 416.5073
Monoisotopic: 416.219888756
Chemical Formula
C24H32O6
InChI Key
WBGKWQHBNHJJPZ-LECWWXJVSA-N
InChI
InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.

Associated Conditions
Pharmacodynamics

Desonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.

Mechanism of action

Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desonide.Investigational
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Desonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desonide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desonide.Approved, Experimental, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Desonide is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Desonide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desonide.Approved, Withdrawn
AldesleukinDesonide may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Desonide can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desonide.Experimental
AloglutamolThe bioavailability of Desonide can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Desonide.Experimental
AluminiumThe bioavailability of Desonide can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Desonide can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Desonide can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Desonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe risk or severity of adverse effects can be increased when Desonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desonide.Approved
AmiodaroneThe serum concentration of Desonide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BDesonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desonide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desonide.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Desonide is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desonide.Approved, Investigational
AntrafenineThe risk or severity of adverse effects can be increased when Desonide is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Desonide can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Desonide.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Desonide.Approved, Investigational
AprepitantThe serum concentration of Desonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Desonide can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Desonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desonide.Approved
AzosemideDesonide may increase the hypokalemic activities of Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Desonide is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Desonide is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desonide.Approved, Investigational
BazedoxifeneThe serum concentration of Desonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Desonide is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Desonide.Experimental
BendroflumethiazideDesonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Desonide.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Desonide.Approved, Investigational
BenzthiazideDesonide may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Desonide.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Desonide.Experimental
Bismuth subcitrate potassiumThe bioavailability of Desonide can be decreased when combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe bioavailability of Desonide can be decreased when combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Desonide can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desonide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desonide.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desonide.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Desonide.Experimental
BumetanideDesonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desonide.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Desonide can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Desonide can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideDesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinThe risk or severity of adverse effects can be increased when Desonide is combined with Capsaicin.Approved
CarbamazepineThe serum concentration of Desonide can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desonide.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Desonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desonide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desonide.Approved, Investigational
CeritinibDesonide may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desonide.Approved, Investigational, Vet Approved
ChlorothiazideDesonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Desonide can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Desonide is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneDesonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desonide.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Desonide is combined with Cimicoxib.Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Desonide is combined with Cisplatin.Approved
ClarithromycinThe serum concentration of Desonide can be increased when it is combined with Clarithromycin.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Desonide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Desonide.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Desonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Desonide can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Desonide can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desonide.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Desonide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Desonide is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Desonide.Approved, Investigational
CyclopenthiazideDesonide may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DaidzeinThe serum concentration of Desonide can be increased when it is combined with Daidzein.Experimental
DanazolDesonide may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Desonide can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Desonide is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Desonide is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Desonide is combined with Demecarium.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desonide.Investigational
DexibuprofenThe risk or severity of adverse effects can be increased when Desonide is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Desonide is combined with Dexketoprofen.Approved, Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Desonide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desonide.Approved, Vet Approved
DienestrolThe serum concentration of Desonide can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Desonide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Desonide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desonide.Approved, Investigational
DipivefrinThe risk or severity of adverse effects can be increased when Desonide is combined with Dipivefrin.Approved
DistigmineThe risk or severity of adverse effects can be increased when Desonide is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Desonide is combined with Donepezil.Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Desonide is combined with Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Desonide.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desonide.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Desonide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Desonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Desonide is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Desonide can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Desonide can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Desonide.Approved
EpitizideDesonide may increase the hypokalemic activities of Epitizide.Experimental
EquolThe serum concentration of Desonide can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Desonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Desonide can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Desonide can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Desonide can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Desonide can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Desonide can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Desonide can be increased when it is combined with Estrone.Approved
Etacrynic acidDesonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Desonide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Desonide.Experimental
Ethinyl EstradiolThe serum concentration of Desonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Desonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desonide.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desonide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desonide.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Desonide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Desonide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desonide.Approved
FenthionThe risk or severity of adverse effects can be increased when Desonide is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desonide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Desonide.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desonide.Experimental
Fish oilThe risk or severity of adverse effects can be increased when Desonide is combined with Fish oil.Approved, Nutraceutical
FleroxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Desonide.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Desonide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Desonide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Desonide.Experimental
FluoxymesteroneDesonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desonide.Approved, Investigational
FosaprepitantThe serum concentration of Desonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Desonide can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideDesonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Desonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Desonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Desonide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Desonide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Desonide is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Desonide is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GinsengThe risk or severity of adverse effects can be increased when Desonide is combined with Ginseng.Approved, Investigational, Nutraceutical
GLPG-0492Desonide may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Desonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Desonide.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desonide.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Desonide is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Desonide is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Desonide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Desonide.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Desonide is combined with Human rabies virus immune globulin.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Desonide is combined with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desonide.Approved, Investigational
HydrochlorothiazideDesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDesonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Desonide can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Desonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Desonide.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Desonide is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Desonide can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Desonide.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Desonide.Approved
IndapamideDesonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Desonide can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Desonide.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Desonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Desonide is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Desonide is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Desonide is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Desonide.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desonide.Withdrawn
ItraconazoleThe serum concentration of Desonide can be increased when it is combined with Itraconazole.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Desonide is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desonide.Experimental
KetoconazoleThe serum concentration of Desonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desonide.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Desonide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Desonide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desonide.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Desonide.Experimental
LopinavirThe serum concentration of Desonide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desonide.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desonide.Approved, Investigational
LumacaftorThe serum concentration of Desonide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desonide.Approved, Investigational
MagaldrateThe bioavailability of Desonide can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Desonide can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Desonide can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Desonide can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Desonide can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desonide.Approved
Magnesium silicateThe bioavailability of Desonide can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Desonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Desonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desonide.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Desonide is combined with Mefloquine.Approved, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Desonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desonide.Approved
MesteroloneDesonide may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Desonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Desonide.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Desonide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Desonide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideDesonide may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desonide.Approved, Vet Approved
MethyltestosteroneDesonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Desonide is combined with Metoclopramide.Approved, Investigational
MetolazoneDesonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Desonide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Desonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Desonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Desonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desonide.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Desonide.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Desonide is combined with Morniflumate.Approved
MoxestrolThe serum concentration of Desonide can be increased when it is combined with Moxestrol.Experimental
MoxifloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desonide.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Desonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Desonide is combined with Nalidixic Acid.Approved, Investigational
NandroloneDesonide may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateDesonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Desonide.Approved, Vet Approved
NefazodoneThe serum concentration of Desonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Desonide can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Desonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desonide.Approved, Investigational
NevirapineThe serum concentration of Desonide can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Desonide is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Desonide.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desonide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desonide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desonide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desonide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Desonide.Vet Approved
OxandroloneDesonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desonide.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Desonide is combined with Oxolinic acid.Experimental
OxymetholoneDesonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desonide.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Desonide.Experimental, Nutraceutical
ParaoxonThe risk or severity of adverse effects can be increased when Desonide is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desonide.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Desonide.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Desonide can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe serum concentration of Desonide can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Desonide.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Desonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desonide.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Desonide.Approved, Investigational
PhenytoinThe serum concentration of Desonide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Desonide is combined with Physostigmine.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desonide.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Desonide is combined with Pipemidic acid.Experimental
PiretanideDesonide may increase the hypokalemic activities of Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desonide.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Desonide is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desonide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Desonide.Experimental
Polyestradiol phosphateThe serum concentration of Desonide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDesonide may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Desonide is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Desonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desonide.Experimental, Investigational
PrimidoneThe serum concentration of Desonide can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Desonide.Experimental
PromestrieneThe serum concentration of Desonide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desonide.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Desonide.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Desonide.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Desonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Desonide is combined with Pyridostigmine.Approved, Investigational
QuinestrolThe serum concentration of Desonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneDesonide may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Desonide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Desonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desonide.Approved, Experimental, Investigational
RifabutinThe serum concentration of Desonide can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Desonide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Desonide can be decreased when it is combined with Rifapentine.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Desonide is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Desonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Desonide.Approved, Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Desonide is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Desonide is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desonide.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Desonide is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Desonide is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desonide.Approved
SaquinavirThe serum concentration of Desonide can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Desonide can be increased when it is combined with Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Desonide is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Desonide.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desonide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desonide.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Desonide can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Desonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Desonide.Investigational
St. John's WortThe serum concentration of Desonide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneDesonide may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololDesonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Desonide can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desonide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Desonide.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Desonide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Desonide.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Desonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Desonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Desonide is combined with Tacrine.Investigational, Withdrawn
TalniflumateThe risk or severity of adverse effects can be increased when Desonide is combined with Talniflumate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desonide.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Desonide is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Desonide.Approved, Withdrawn
TelithromycinThe serum concentration of Desonide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Desonide.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desonide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Desonide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desonide.Approved
TestosteroneDesonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone cypionateThe risk or severity of edema formation can be increased when Testosterone cypionate is combined with Desonide.Approved
Testosterone enanthateThe risk or severity of edema formation can be increased when Testosterone enanthate is combined with Desonide.Approved
Testosterone propionateDesonide may increase the fluid retaining activities of Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Desonide.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Desonide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desonide.Approved
TiboloneThe serum concentration of Desonide can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desonide.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desonide.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desonide.Approved
TorasemideDesonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Desonide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Desonide is combined with Triamcinolone.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desonide.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Desonide is combined with Trichlorfon.Vet Approved
TrichlormethiazideDesonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Desonide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desonide.Approved
TromethamineThe bioavailability of Desonide can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Desonide is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Desonide is combined with Tubocurarine.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Desonide is combined with Typhoid Vaccine.Approved
TyrothricinThe risk or severity of adverse effects can be increased when Desonide is combined with Tyrothricin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desonide.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Desonide is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VoriconazoleThe serum concentration of Desonide can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDesonide may increase the anticoagulant activities of Warfarin.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Desonide is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desonide.Approved, Investigational
ZeranolThe serum concentration of Desonide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Desonide.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desonide.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015389
KEGG Drug
D03696
PubChem Compound
5311066
PubChem Substance
46506186
ChemSpider
4470603
ChEBI
204734
ChEMBL
CHEMBL1201109
Therapeutic Targets Database
DAP001188
PharmGKB
PA164776996
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Desonide
ATC Codes
S01BA11 — DesonideD07BB02 — Desonide and antisepticsD07AB08 — Desonide
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceHealthy Volunteers1
3CompletedTreatmentAtopic Dermatitis (AD)1
3RecruitingTreatmentAtopic Dermatitis Eczema1
3Unknown StatusTreatmentAtopic Dermatitis (AD) / Dermatitis, Eczematous1
4CompletedTreatmentAtopic Dermatitis (AD)2
4CompletedTreatmentAtopic Dermatitis (AD) / Dermatitis, Eczematous1
4CompletedTreatmentHyperpigmentation1
4Not Yet RecruitingTreatmentPsoriasis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Actavis Group
  • Ameri-Pac Inc.
  • Contract Pharm
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DPT Laboratories Ltd.
  • E. Fougera and Co.
  • Galderma Laboratories
  • Intendis Inc.
  • Ivax Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Nycomed Inc.
  • Palmetto Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmedix
  • Physicians Total Care Inc.
  • Stiefel Labs
  • Taro Pharmaceuticals USA
Dosage forms
FormRouteStrength
LotionTopical.05 %
GelTopical.5 mg/g
LotionTopical.5 mg/mL
OintmentTopical.5 mg/g
CreamTopical.5 mg/g
LotionTopical.5 mg/g
CreamTopical0.05 %
OintmentTopical0.05 %
CreamTopical.05 %
OintmentTopical.05 %
CreamTopical.03 g/60g
CreamTopical.5 mg
OintmentTopical.5 mg
Aerosol, foamTopical.5 mg/g
Aerosol, foamTopical0.05 %
Prices
Unit descriptionCostUnit
DesOwen Lot w/Cetaphil Cream 0.05% Kit Box255.84USD box
Desowen 0.05% ointment kit217.2USD kit
Desowen 0.05% cream kit212.4USD kit
DesOwen 0.05% Lotion 118ml Bottle183.17USD bottle
Desonide powder152.39USD g
DesOwen 0.05% Lotion 59ml Bottle123.38USD bottle
Desonide 0.05% Lotion 118ml Bottle76.75USD bottle
Desonide 0.05% Lotion 59ml Bottle50.86USD bottle
Desonide 0.05% Ointment 60 gm Tube41.76USD tube
Desonide 0.05% Cream 60 gm Tube41.48USD tube
Desonide 0.05% Ointment 15 gm Tube16.09USD tube
Desonide 0.05% Cream 15 gm Tube16.07USD tube
Desowen 0.05% cream2.43USD g
Desonide 0.05% cream0.81USD g
Desocort 0.05 % Ointment0.32USD g
Pms-Desonide 0.05 % Cream0.28USD g
Pms-Desonide 0.05 % Ointment0.28USD g
Desocort 0.05 % Lotion0.16USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8460641No2008-11-052028-11-05Us
US8962000No2005-08-312025-08-31Us
US6730288No1999-09-082019-09-08Us
US7029659No1999-09-082019-09-08Us
US6387383No2000-08-032020-08-03Us
US9492384No2005-08-312025-08-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)257-260Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.
water solubilityPractically insolubleNot Available
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0594 mg/mLALOGPS
logP2.31ALOGPS
logP1.9ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity112.06 m3·mol-1ChemAxon
Polarizability44.77 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9764
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6162
P-glycoprotein substrateSubstrate0.7998
P-glycoprotein inhibitor INon-inhibitor0.5837
P-glycoprotein inhibitor IIInhibitor0.6045
Renal organic cation transporterNon-inhibitor0.7573
CYP450 2C9 substrateNon-substrate0.8268
CYP450 2D6 substrateNon-substrate0.9078
CYP450 3A4 substrateSubstrate0.7545
CYP450 1A2 substrateNon-inhibitor0.909
CYP450 2C9 inhibitorNon-inhibitor0.8729
CYP450 2D6 inhibitorNon-inhibitor0.9544
CYP450 2C19 inhibitorNon-inhibitor0.9521
CYP450 3A4 inhibitorNon-inhibitor0.536
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9129
Ames testNon AMES toxic0.8938
CarcinogenicityNon-carcinogens0.949
BiodegradationNot ready biodegradable0.9766
Rat acute toxicity2.5316 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9573
hERG inhibition (predictor II)Non-inhibitor0.67
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Ketals / Alpha-hydroxy ketones / 1,3-dioxolanes / Secondary alcohols / Cyclic ketones
show 5 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxosteroid / 3-oxo-delta-1,4-steroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / Delta-1,4-steroid
show 18 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
11beta-hydroxy steroid, cyclic ketal, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid, 21-hydroxy steroid (CHEBI:204734)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, Lightman SL: Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci. 2010 Apr 28;30(17):6106-15. doi: 10.1523/JNEUROSCI.5332-09.2010. [PubMed:20427668]
  2. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
  3. Otte C, Wust S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA: Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. J Clin Endocrinol Metab. 2010 Jun;95(6):2885-91. doi: 10.1210/jc.2009-2251. Epub 2010 Apr 6. [PubMed:20371666]

Drug created on May 16, 2007 11:31 / Updated on July 16, 2018 21:21